Egis Gyogyszergyar Rt.

Virostatics Srl

Bayer Pharma Aktiengesellschaft

Lead Discovery Center Gmbh

Vichem Chemie Kutató Kft.

Zoltán Greff

Gyula Simig

Jozsef Barkoczy

György Kéri

Zoltán Varga

Kalman Nagy

László Örfi

Franco Lori

Antonio Solinas

James Chafouleas

Davide De Forni

Peter Kotay Nagy

Zsuzsa Szent Kirallyi

Zoltan Ratkai

Wilfried Schwab

Gabor Gigler

Laszlo Balazs

Gabor Blasko

József Barkóczy

Ferenc Lorant Bartha

Andras Egyed

György Lévay

Gábor Szénási

Gábor Németh

Axel Choidas

Bert Klebl

Edmund Hoppe

Gábor Gigler

Karoly Tihanyi

László Gábor Hársing

Doris Hafenbradl

Gerhard Müller

Don Simpson

Klaus Godl

István Ling

Geza Szabo

Joelle Le

Jackie Macritchie

Miklós Végh

Bernadett Martonné Markó

Peter Seres

Imre Doman

Peter Habenberger

Gyorgyi Vereczkeyne Donath

Christian Hartung

Thomas Herget

Andrea Missio

Csaba Szántai Kis

Birgit Zech

Jose Bravo

John Harris

László Õrfi

Vladimir Savic

Brad Sherborne

Zoltán Rátkai

Géza Szabó

Alexander Backes

Matt Cotten

Györgyi Vereczkeyne Donath

Ferenc Barta

Bernadett Martonné Marko

Ola Engkvist

György Levay

Beatrice Felber

Annamaria Simo

Achim Freisleben

László Orfi

Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

The invention refers to novel 2,3-benzodiazepine derivatives of formula (I) and pharmaceutical compositions containing the same as the active ingredient. The novel compounds antipasmodic, muscle relaxant and neuroprotective activities. In formula I; X represents a hydrogen atom, a chloro atom or a methoxy group; Y stands for a hydrogen atom or a halo atom; Z means a methyl group or a chloro atom; R is a Calkyl group or a group of the formula &#x2014;NRR, wherein Rand Rrepresent, independently, a hydrogen atom, a Calkyl group, a Calkoxy group or a Ccycloalkyl group. 

2, 3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient

The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin 

Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin

The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein Rstands for methyl, formyl, carboxy, cyano, &#x2014;CH&#x2550;NOH, &#x2014;CH&#x2550;NNHCONHor &#x2014;NRR, wherein Rand Rindependently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris nitro or amino; Rstands for hydrogen, lower alkanoyl or CO&#x2014;NRR, wherein Rand Rindependently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris hydrogen or lower alkyl; the dotted lines have the following meaning: if Rand Rare not present, the bond between positions Cand Cis a single bond and the bond between positions Cand Nis a double bond; if Rand Rare present, the bonds between positions Cand Cand between position Cand Nare single bonds; and if Ris present and Ris missing, the bond between positions Cand Cis a double bond and the bond between positions Cand Nis a single bond) and salts thereof. The invention compounds have neuroprotective effect.

2,3-benzodiazepine derivatives

The invention relates to a process for the preparation of amorphous atorvastatin calcium by recrystallization of crude atorvastatin from an organic solvent which comprises dissolving crude amorphous atorvastatin calcium in a lower alkanol containing 2-4 carbon atoms or a mixture of such alkanols under heating and isolating the amorphous atorvastatin calcium precipitated after cooling. The atorvastatin calcium obtained is a known valuable agent useful in treating hyperlipidemia and hypercholestrolemia.

Process for the preparation of amorphous atorvastatin calcium

Growing community of inventors

Budapest, Hungary

Zoltán Greff